Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPACE: Varenicline for Smoking Relapse Prevention in COPD
NCT02888444Phase 3Terminated
- Sponsor
- The University of Auckland
- Start
- Jul 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nicotine dependence comparing Varenicline with Placebo (2 arms). Primary endpoint: Continuous abstinence at 12 weeks. Started Jul 2017; status: terminated.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT02888444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888444.